Now you can give your low-risk AS patients a chance at the lowest-risk option
- TAVI offers the low-risk indication and proven superiority* over surgery (sAVR)
Low risk patients are younger and healthier and, for them, sAS is their primary concern
Low-risk patients are healthier1
Low-risk patients are younger1
Low-risk patients have fewer comorbidities
PARTNER 3 Trial(n=950)
PARTNER IIA Trial (n=938)
PARTNER IA Trial (n=657)
CABG, coronary artery bypass grafting; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; KCCQ, Kansas City Cardiomyopathy Questionnaire; NYHA, New York Heart Association; PPM, permanent pacemaker; STS, Society of Thoracic Surgeons.
- With the low-risk indication and proven superiority over sAVR* nothing stands in the way of a TAVI evaluation for your patients1
Only SAPIEN 3 TAVI was proven superior to surgery on the primary endpoints (all-cause death, all-stroke, or rehospitalisation)1, 7
PARTNER 3 Low-Risk Trial
Primary Endpoint: Baseline Death, Stroke or Rehospitalisation
Change from baseline in KCCQ-OS score at 1 month, 6 months and 1 year with SAPIEN 3 TAVI 4
KCCQ-OS, Kansas City Cardiomyopathy Questionnaire–Overall Summary.
- With half-a-million transcatheter heart valve implants and 18 years of experience, TAVI has evolved to deliver faster procedures, shorter hospital stays, less rehospitalisation, and low pacemaker rates1
- Additionally, SAPIEN 3 TAVI has demonstrated substantially improved early and sustained QoL benefits in low-risk patients with sAS at 1 month, 6 months and 1 year compared with sAVR†4
Proven to be superior to surgery on primary end points in PARTNER 3, refer your low-risk patients with sAS for TAVI evaluation
Valve durability and future treatment options are a key consideration in low-risk patients with sAS and longer life expectancies8-10
Especially in younger and healthier AS patients, valve durability and future treatment options should be considered.
- 5 year-data from PARTNER 2S3i shows long-term durability with SAPIEN 3 TAVI is equivalent to surgery, with11
- Sustained improvements in haemodynamic performance‡
- Similar rates of reintervention for TAVI vs sAVR§
- Similar rates of haemodynamic valve deterioration (HVD) and bioprosthetic valve failure (BVF) for TAVI vs sAVR
Keep your low-risk patients active with a TAVI that is supported by real-world durability data
- ViV is a viable alternative to redo (reoperative) surgery for degenerate sAVR or TAVI10
- Compared with redo surgery, ViV TAVI is associated with:12
- Shorter stays in ICU
- Reduced time on ventilation
- Lower transfusion requirements
- ViV TAVI is associated with lower early mortality and morbidity, and increased survival at 5 years compared with redo (reoperative) surgery13
No matter what their future brings, know they have the option of ViV TAVI
Check our latest articles
Stay informed with our newsletter
Thank you!
For signing up to the monthly Edwards Lifesciences TAVI newsletter. You will now receive emails on the latest developments and industry insights on aortic stenosis
References
- 1Mack MJ, et al. N Engl J Med. 2019;380(18):1695—1705 and supplementary material.
- 2Leon MB, et al. N Engl J Med 2016;374:1609—1620 and supplementary material.
- 3Smith CR et al. N Engl J Med 2011;364:2187—2198 and supplementary material.
- 4Baron SJ, et al. J Am Coll Cardiol. 2019;74(23):2833—2842.
- 5Baron SJ, et al. JACC Cardiovascr Interv. 2018;11(12):1188—1198.
- 6Reynolds MR, et al. J Am Coll Cardiol 2012;60(6):548—558.
- 7Leon MB & Mack MJ. PARTNER 3: Transcatheter or Surgical Aortic Valve Replacement in Low Risk Patients with Aortic Stenosis. Presented at: American College of Cardiology Annual Scientific Session (ACC 2019), New Orleans, LA, March 17, 2019.
- 8Rodriquez-Gabella T, et al. J Am Coll Cardiol. 2017;70(8):1013—1028.
- 9Kuck K, et al. Cardiologist 2020;14: 182—204.
- 10Sathananthan J, et al. Catheter Cardiovasc Interv. 2021;97(3):E431—E437.
- 11Kodali SK, et al. Presentation at the Transcatheter Valve Therapies (TVT) Summit virtual event: TVT Connect 2020. Available at:
https://www.tctmd.com/slide/sapien-3-transcatheter-aortic-valve-replacement-compared-surgery-intermediate-risk-patients-0 (accessed March 2021). - 12Silaschi M et al. Interactive Cardiovasc Thorac Surg. 2017;24(1):63—70.
- 13Tam DY, et al. JACC Cardiovasc Interv. 2020;13(6):765—774.